Week 3: Rheumatology
Imaging of inflammatory rheumatic diseases
Arthritis = inflamed joint.
DD painful, swollen joints:
● Gout: (jicht) is an inflammation in the joint (type of arthritis), often in the feet or toe.
○ Erosion can happen in chronic gout → caused by tophi
○ Tophi = deposit of crystalline uric acid at the joint’s surface.
● Pseudo-gout: also inflammation of the joint.
○ It is caused by a deposit of calcium salts in intra-articular cartilage. These
crystals can be seen on ultrasound and X-rays.
○ Often pre-existent osteoarthritis.
Rheumatoid arthritis:
● It can start in one large joint.
● X-rays can show erosion at soon as 3-4 months after diagnosis.
● Conventional X-ray: used to asses erosions and joint space narrowing. Cannot see
synovitis!
● Early RA: Blood test with anti-CCP+, swelling and pain in the joints
● Difference between osteoarthritis (OA) and RA: OA
= bones grew together in X-ray (no space between
the bones for cartilage) and the bones thicken
(therefore lighter on the X-ray).
● Imaging is needed for early diagnostics, monitoring
efficacy therapy and prognosis.
○ Ultrasound: more red on the ultrasound
indicates more Doppler power → more
hyperperfusion (increased blood flow) →
inflammation (synovitis). >>>>>>
<<<<MRI: white areas on the MRI indicate
water → inflammation. After treatment white
spaces have to become less → monitor the
efficacy of the therapy.
PET: can trace for inflammation or for new bone formation.
● Macrophages: using the folate receptor beta for macrophages.
● B cells: use anti-CD20 (Rituximab)
Spondyloarthritis:
● Mainly affect the spine → bamboo spine.
● Inflammation of sacroiliac joint → could eventually
grow together
● New bone formation is used as a tracer for PET
scans.
, Large vessel vasculitis:
● Giant cell arteritis (GCA): inflammation of the lining of the arteries.
● Ultrasound: Halo Sign = wall thickening around the lumen.
Immunology and rheumatic diseases
Problems RA: once a patient has it, it will only get worse. And we do not know how fast it will
get worse.
Development of RA: genetic susceptibility, immune response & trigger.
Diseases:
● Rheumatoid arthritis (RA): Class 2 MHC (HL-DR) and formation of auto-antibodies.
○ Treatment via anti-TNF (Infliximab)
● Ankylosing spondylitis (AS) = axial SpA: Class 1 MHC (HLA-B27) and no formation of
auto-antibodies.
● Henoch-Schonlein purpura: vasculitis of small bloodvesssels. Happens more in
children. Formation of auto-antibodies.
● Systemic lupus erythematosus (SLE): multiple clinical manifestations, like skin, joints,
kidneys etc. Formation of auto-antibodies.
○ Treatment via anti-CD20 (Ritxumab) → works against the lymphoma cells.
○ Or treatment via Type 1 IFN → blocking type 1 IFN (Anifrolumab).
New developments in rheumatology research
The heterogeneity of the diseases hampers diagnosis and therapy, and the need for
research:
● Diagnosis: difficult due to variability and most time after the joint inflammation
● Therapy: many good treatments, but all very expensive. There is still no cure and
there is some non-responsiveness.
Mapping early immune abnormalities in RA:
● There are a lot of environmental factors that play a role before the onset of RA.
● The pre-clinical risk with autoantibodies, serum inflammatory changes and airway
abnormalities.
● Risk factors of the environment are smoking and high BMI.
● Association of arthritis development with synovial T cell infilatrion → indicate
differences in synovium before the onset of disease. But there is no inflammation
seen in this phase → resident T cells.
● These changes could be due to synovial stromal cells, and where are the
auto-antibodies produced in the risk phase?
● In the lymph node in the risk phase, IL-10 goes down → anti-inflammatory.
○ Hypothesis 1: Mesenchymal stromal cells in lymphoid organs and synovial
tissue are defective before the onset of disease → microenvironment with no
good controlled immune response.
○ Hypothesis 2: tolerance lost in other places → production antibodies →
epitope spreading → second hit in joints → chronic arthritis.
Voordelen van het kopen van samenvattingen bij Stuvia op een rij:
Verzekerd van kwaliteit door reviews
Stuvia-klanten hebben meer dan 700.000 samenvattingen beoordeeld. Zo weet je zeker dat je de beste documenten koopt!
Snel en makkelijk kopen
Je betaalt supersnel en eenmalig met iDeal, creditcard of Stuvia-tegoed voor de samenvatting. Zonder lidmaatschap.
Focus op de essentie
Samenvattingen worden geschreven voor en door anderen. Daarom zijn de samenvattingen altijd betrouwbaar en actueel. Zo kom je snel tot de kern!
Veelgestelde vragen
Wat krijg ik als ik dit document koop?
Je krijgt een PDF, die direct beschikbaar is na je aankoop. Het gekochte document is altijd, overal en oneindig toegankelijk via je profiel.
Tevredenheidsgarantie: hoe werkt dat?
Onze tevredenheidsgarantie zorgt ervoor dat je altijd een studiedocument vindt dat goed bij je past. Je vult een formulier in en onze klantenservice regelt de rest.
Van wie koop ik deze samenvatting?
Stuvia is een marktplaats, je koop dit document dus niet van ons, maar van verkoper nooralkemade. Stuvia faciliteert de betaling aan de verkoper.
Zit ik meteen vast aan een abonnement?
Nee, je koopt alleen deze samenvatting voor €6,49. Je zit daarna nergens aan vast.